pubmed-article:18698826 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18698826 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
pubmed-article:18698826 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
pubmed-article:18698826 | lifeskim:mentions | umls-concept:C1515568 | lld:lifeskim |
pubmed-article:18698826 | lifeskim:mentions | umls-concept:C2606016 | lld:lifeskim |
pubmed-article:18698826 | pubmed:issue | 18 | lld:pubmed |
pubmed-article:18698826 | pubmed:dateCreated | 2008-9-15 | lld:pubmed |
pubmed-article:18698826 | pubmed:abstractText | An efficient enantioselective synthesis of (+)-isofregenedol was achieved in 13 steps from commercially available cyclohexene oxide without the use of protecting groups. The tetrahydronaphthalenic core of isofregenedol was obtained via a gold(I)-catalyzed benzannulation recently developed in our laboratory. | lld:pubmed |
pubmed-article:18698826 | pubmed:language | eng | lld:pubmed |
pubmed-article:18698826 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18698826 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18698826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18698826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18698826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18698826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18698826 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18698826 | pubmed:month | Sep | lld:pubmed |
pubmed-article:18698826 | pubmed:issn | 1520-6904 | lld:pubmed |
pubmed-article:18698826 | pubmed:author | pubmed-author:BarriaultLoui... | lld:pubmed |
pubmed-article:18698826 | pubmed:author | pubmed-author:RiouMaximeM | lld:pubmed |
pubmed-article:18698826 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:18698826 | pubmed:day | 19 | lld:pubmed |
pubmed-article:18698826 | pubmed:volume | 73 | lld:pubmed |
pubmed-article:18698826 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18698826 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18698826 | pubmed:pagination | 7436-9 | lld:pubmed |
pubmed-article:18698826 | pubmed:meshHeading | pubmed-meshheading:18698826... | lld:pubmed |
pubmed-article:18698826 | pubmed:meshHeading | pubmed-meshheading:18698826... | lld:pubmed |
pubmed-article:18698826 | pubmed:meshHeading | pubmed-meshheading:18698826... | lld:pubmed |
pubmed-article:18698826 | pubmed:meshHeading | pubmed-meshheading:18698826... | lld:pubmed |
pubmed-article:18698826 | pubmed:meshHeading | pubmed-meshheading:18698826... | lld:pubmed |
pubmed-article:18698826 | pubmed:meshHeading | pubmed-meshheading:18698826... | lld:pubmed |
pubmed-article:18698826 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18698826 | pubmed:articleTitle | De novo synthesis of (+)-isofregenedol. | lld:pubmed |
pubmed-article:18698826 | pubmed:affiliation | Department of Chemistry, 10 Marie Curie, University of Ottawa, Ottawa, Canada K1N 6N5. | lld:pubmed |
pubmed-article:18698826 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18698826 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |